VK2735

What is VK2735?

VK2735 is an investigational weight-loss and metabolic drug from Viking Therapeutics that activates two gut hormone receptors at once, the GLP-1 receptor and the GIP receptor. That dual-incretin design is the exact same mechanism behind tirzepatide, the approved drug sold as Mounjaro and Zepbound. The whole reason I'm scoring VK2735 is that it sits at the earliest stage of the next-generation incretin batch, and its early numbers are strong enough to take seriously. In its one peer-reviewed trial, the injectable form drove about 14.7 percent weight loss in just 13 weeks. That is genuinely competitive with the best in class, and I dig into that study in the Upside Rationale below.

From the BioHarmony report, reviewed 2026-09-08.

How it is thought to work

Activates GLP-1 and GIP receptors together for appetite suppression, slowed gastric emptying, and glucose-dependent insulin release

Safety watch-outs

• Severe or persistent abdominal pain, especially radiating to the back (possible pancreatitis): stop and seek care.
• A neck lump, hoarseness, or trouble swallowing (the class carries a thyroid C-cell tumor warning): stop and consult a clinician.
• Severe, ongoing vomiting or dehydration: stop and rehydrate, and seek care if it does not settle.
• Any unverified or research-chemical-grade source: do not inject or ingest, since purity and contamination are unknown.

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for VK2735 yet.

Related peptides for weight & metabolic

1. 6.5/10MOTS-cWorth tryingWeight & metabolicNot FDA approvedMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
2. 6.2/10IpamorelinWorth tryingRecoveryNot FDA approvedIpamorelin is a selective growth-hormone secretagogue with strong receptor selectivity but almost no human efficacy data: its only completed human efficacy trial…
3. 6.1/10TirzepatideWorth tryingWeight & metabolicFDA-approved product existsTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
4. 6.0/10Semaglutide (GLP-1 Agonist)Worth tryingWeight & metabolicFDA-approved product existsSemaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 6.0-6.5/10 score holds…